Why this story
- Why it matters
- The long interval between infusion and symptoms helps explain why a retrospective study across several centers was useful for estimating this complication’s frequency.
- Attention gap
- Ori’s seven-day headline-index search recorded no matches among 11 outlets. The publisher read the full journal paper, including its case flowchart and cause-of-death breakdown. The recorded count reflects the limits of Ori’s search.
Researchers at eight U.S. institutions found 39 cases of delayed bowel inflammation among 1,308 people who received cilta-cel, a CAR-T therapy for multiple myeloma, through September 2025. The estimated frequency was 3.0%, with a 95% confidence interval of 2.1% to 4.1%.
The team also reviewed 54 suspected cases, classifying 41 as confirmed or probable. Symptoms appeared a median of 75 days after infusion, and 30 of those 41 people required intravenous nutrition.
Seventeen of the 41 died while the inflammation was active. The researchers attributed five deaths directly to the condition or its complications. They recorded ten deaths involving infectious complications and two from other causes.
What the evidence cannot tell us
- These retrospective estimates come from eight centers. The 41-case review and the 1,308-person incidence cohort answer different questions.
What to watch
Prospective follow-up can clarify how often this complication occurs and which factors identify patients at higher risk.
Read the sources. Credit the work.
The reporting and documents behind this brief, linked directly to the source. Verified publisher and author credits appear where available; other entries show their actual website address. Several links may draw on the same underlying reporting or research.
Nature Medicine
Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy (opens in a new tab)nature.com · November 19, 2026
Primary document / sourceContent read for this publication · November 22, 2026Publisher credit checked November 22, 2026. View credit on the source page (opens in a new tab).
This story was written and checked using AI against the linked evidence. No routine human review is claimed. Read the method.
Suggest an update or correctionPublished corrections